Insurance Curator Payers squeeze margins and signal higher premiums as drug‑pricing volatility forces cost‑shifting strategies
By [Staff Writer]
Who: Major private and public health insurers and plan sponsors. What: Are tightening benefit designs, expanding utilization controls and proposing higher premiums after an era of volatile drug prices and unprecedented specialty‑drug uptake. When: Developments accelerated through 2024–2025 and are shaping premium filings and plan designs for 2026. Where: Primarily the United States, with parallel pressures in other high‑income health systems. Why: Rapid growth in high‑cost specialty therapies — notably GLP‑1 weight‑loss and diabetes drugs, expensive gene and cell therapies, and ongoing list‑price inflation — combined with changing federal drug‑pricing rules and shifting rebate and negotiation dynamics have driven spending spikes that are compressing insurers’ medical margins and prompting cost‑shifts to employers and consumers. (kff.org)
Health insurers and plan sponsors say they face an unprecedented combination of pricing shocks and utilization shifts that are eroding underwriting margins and forcing benefit redesigns that will raise out‑of‑pocket costs for some consumers and push employers to rework their offerings. In publicly filed rate justifications, earnings reports and industry surveys, payers have pointed to the fast growth of high‑cost specialty medicines — especially GLP‑1 class therapies used for diabetes and weight loss — as a central near‑term driver of higher pharmacy spending, even as federal drug‑price negotiation programs and other reforms alter the landscape for Medicare and Medicaid. (kff.org)
Drug volatility and the GLP‑1 shock
The last two years have seen both abrupt price moves and rapid patient uptake of a handful of therapies that carry high per‑patient costs. GLP‑1 and related agents — marketed as Wegovy, Ozempic, Mounjaro and Zepbound among others — have produced sharp increases in use for weight management well beyond initial projections, and insurers and employers report materially higher spending tied to those drugs. Employers surveyed by KFF said large firms had experienced year‑over‑year prescription‑drug spending pressures tied to GLP‑1s and many employers indicated they were unlikely to begin covering the drugs for weight loss in the near term. Insurers and PBMs have reacted by narrowing coverage, adding utilization requirements or excluding the drugs entirely for weight‑loss indications in some plan designs. (kff.org)
“Employers have nothing new in their arsenal that can address most of the drivers of their cost increases and that could well result in an increase in deductibles and other forms of employee cost‑sharing again,” KFF Chief Executive Drew Altman told reporters when discussing insurer filings and employer surveys. (streetinsider.com)
The GLP‑1 phenomenon is only one element of a broader specialty‑drug surge. Payers also face expensive one‑time gene and cell therapies, multiple high‑list‑price oncology launches and frequent manufacturer price increases on older brands. Those dynamics feed into year‑to‑year volatility in pharmacy spend that is harder for actuaries to forecast and to price into premiums in advance. Analysts and consulting firms have forecast medical cost trends in the high single digits for 2025–2026, driven in part by prescription drug spending. (paulkeckley.com)
How volatility hits insurer margins
Insurers translate medical claims into an industry metric known as the medical loss ratio (MLR) — the share of premium dollars applied to health care services. When unexpected drug costs spike or utilization runs above assumptions, MLRs rise and underwriting margins compress. Several large U.S. insurers have reported elevated MLRs in recent quarters and have told investors that drug costs and higher utilization squeezed results and complicated annual guidance. Cigna and other payers flagged rising medical costs as a material contributor to weaker‑than‑expected results in 2024–2025 quarters. (healthcaredive.com)
At the same time, federal policy has altered the mix of where savings and costs show up. The Inflation Reduction Act (IRA) and subsequent Part D redesign created a new set of price negotiations and out‑of‑pocket caps that reduce some drug costs for Medicare beneficiaries, but they also change manufacturer rebate and pricing dynamics in ways that affect commercial plans and PBM contracts. The federal program’s initial negotiation rounds and subsequent administrative actions have already changed price expectations for high‑cost drugs and prompted private payers to reassess assumptions about future list‑price trajectories and rebateability. Officials from the Centers for Medicare & Medicaid Services (CMS) have noted that certain Medicare premiums for 2026 are expected to be stable or even decline because of redesign effects, but commercial and employer plans face separate pressures. (cms.gov)
Insurers’ immediate responses: benefit redesign and utilization management
Faced with margin pressure, payers are deploying three broad strategies: (1) they are tightening coverage rules (prior authorization, step therapy, documentation requirements); (2) they are narrowing formularies or excluding classes of drugs for certain uses (notably GLP‑1s for weight loss); and (3) they are seeking higher premiums or shifting more costs to enrollees via higher copays and deductibles.
Regulators and researchers have documented a marked rise in utilization management. Medicare Advantage plans, which enroll nearly half of Medicare beneficiaries, processed nearly 53 million prior authorization determinations in 2024, a substantial volume that reflects growing use of pre‑service checks for higher‑cost items and services. While most MA requests were approved, denials increased, and appeals — when filed — were frequently overturned, which raises questions about delays in access as well as administrative burden on providers and patients. Payers say expanded prior authorization is a tool to curb inappropriate use and ensure clinical appropriateness; critics say it can delay needed care. (kff.org)
On formularies, multiple insurers and PBMs have limited routine coverage of GLP‑1 products for weight‑loss indications, restricting access to diabetes patients or to members who meet stringent clinical criteria tied to BMI and comorbidities. Employers and consulting groups report a mix of approaches: some self‑insured employers added utilization controls, others excluded the medicines entirely for weight loss, and several large PBMs altered formulary placement, all designed to dampen the short‑term cost shock. KFF’s employer survey found that most large firms saw GLP‑1 spending exceed expectations and many are reluctant to expand coverage. (kff.org)
“We exclude weight loss, the entire anti‑obesity category. We had to make the business decision to pull the whole category,” a benefits manager in a large retail firm told researchers collecting employer perspectives. “Rebates got dramatically worse. We made the business decision to pull the whole category.” (healthsystemtracker.org)
Cost‑shifting and premium signals
Insurers’ pricing materials and rate filings for 2026 show an industry grappling with how much of the drug‑driven cost shock can be absorbed and how much must be passed to buyers. In ACA marketplace filings analyzed by KFF, insurers proposed a median premium increase of 15 percent for 2026 in many markets — the largest jump since 2018 — citing rising health care prices and the growing use of specialty drugs as key drivers. Separately, employer surveys and Mercer’s employer cost forecasts projected mid‑single‑digit increases in employer health costs for 2025–2026, with many employers anticipating higher contributions or increased cost‑sharing for workers. (kff.org)
Some federal rules provide countervailing pressure. CMS projected that average Medicare Advantage and Part D premiums would be stable or decline slightly for 2026 due in part to program redesign and rebates, a dynamic that may blunt patient premium growth for Medicare but leave commercial and employer plans to bear more of the volatility. The split effect — downward pressure on some public program premiums and upward pressure on commercial plan premiums — complicates the industry outlook. (cms.gov)
Insurers’ public statements and filings reflect the tension. Cigna’s finance team highlighted that higher utilization in individual markets and higher stop‑loss claims had elevated their medical loss ratio, even while the company continued to pursue disciplined pricing actions. CVS Health, which operates a major PBM, noted mixed effects from changes to Medicare Part D and prior‑period reserve adjustments in SEC filings while still warning of underlying volatility. (healthcaredive.com)
The patient and provider impact
For patients, the immediate consequences are more restrictive coverage policies, higher cost‑sharing in some employer plans and more administrative barriers. The KFF analysis of MA prior authorization data shows that while most prior authorization requests are ultimately approved, denials and the appeals process can delay care and create additional work for clinicians and patients. Employers report that higher deductibles and copays are likely outcomes as firms try to control plan costs. (kff.org)
Doctors and specialty societies warn that excessive utilization management can impede access to clinically appropriate care. At conferences and in reporting, cardiologists and endocrinologists have described more stringent prior‑authorization thresholds for GLP‑1 prescriptions in some plans — for example, requiring earlier interventions or evidence of specific comorbid disease — even when clinical trials support cardiovascular or metabolic benefits in selected populations. Clinicians say the administrative friction risks undermining outcomes if patients cannot obtain timely treatment. (medscape.com)
International perspectives: shared pressure, different levers
The dynamic is not unique to the United States. High‑income countries also face pressure from new expensive therapies, but they rely more on centralized price negotiation and health technology assessment to blunt cost shocks. National payers in England, Canada and Australia limit routine access or negotiate prices before broad coverage for high‑cost therapies; private insurers in those systems therefore play a smaller role in managing drug spending but still confront pressures in private markets and employer plans. For example, the NHS has constrained routine prescribing for GLP‑1s because of capacity and service‑delivery limits even as private clinics expanded access at out‑of‑pocket prices; provincial drug programs in Canada generally limit coverage of GLP‑1s for weight loss, and private plans vary. OECD and national data also underscore that U.S. per‑capita drug spending remains far higher than many peer countries, a structural source of insurer exposure in the U.S. market. (medscape.com)
Policy levers and the road ahead
Policymakers have moved to address both prices and access. The IRA’s negotiation authority and caps on out‑of‑pocket prescription spending for Medicare beneficiaries are already changing incentives and producing measurable federal savings in early rounds, according to government summaries. At the same time, the federal debate over ACA premium subsidies — and whether enhanced tax credits will be extended — shapes how much of insurers’ higher costs can be absorbed by taxpayers versus passed to unsubsidized enrollees. Insurer filings emphasize that expiration of temporary pandemic-era premium credits would add to consumer premium exposure. (politico.com)
Industry executives argue that a mix of tools — better negotiated prices, greater use of biosimilars and generics, outcomes‑based contracts and intelligent utilization management — can blunt future shocks without unduly restricting clinically appropriate access. “This pressure was manageable due to the smaller relative size of our ACA book, aided by our disciplined pricing actions over the past two years,” Cigna’s CFO Ann Dennison said in describing how the company is responding to cost increases while trying to hold margins. (healthcaredive.com)
But analysts warn the immediate path will likely include more cost‑shifting. KFF’s review of insurer filings shows many carriers’ stated justification for premium increases draws directly to higher hospital and drug prices; employer surveys indicate many firms are considering higher employee cost‑sharing; and payers are increasingly restrictive in formularies and utilization protocols. Those moves can stabilize payers’ near‑term finances but transfer more risk to patients and employers and raise questions about long‑term affordability and access. (kff.org)
Conclusion: recalibration in an unstable market
Payers in high‑income countries face a period of recalibration. Rapid innovation in drug therapy, combined with shifting federal pricing rules and unpredictable utilization patterns, has created a new normal of drug‑pricing volatility. Insurers are responding with tighter benefit designs, increased utilization management and, in many markets, signals of higher premiums. The resulting cost‑shifts will test employers, patients and policymakers alike: employers must decide how much to preserve benefits for workers, patients must navigate more complex access rules, and policymakers must weigh whether public interventions should do more to stabilize markets and protect consumers.
If public programs and private payers fail to build durable mechanisms to share risk without punitive cost‑shifting, the next policy cycle is likely to center on reconciling innovation incentives with more predictable, equitable coverage models — a political and actuarial challenge that will shape health coverage debates through 2026 and beyond. (kff.org)
Sources: KFF analyses and surveys; Centers for Medicare & Medicaid Services notices and press releases; Mercer employer surveys; insurer earnings reports and SEC filings; Reuters and industry reporting on drug pricing and GLP‑1 developments; Peterson‑KFF Health System Tracker employer perspectives; CMS and market data on Medicare Advantage prior authorization. (kff.org)